These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26593062)

  • 1. Structure-Activity Relationship Studies of Amino Acid Substitutions in Radiolabeled Neurotensin Conjugates.
    Mascarin A; Valverde IE; Mindt TL
    ChemMedChem; 2016 Jan; 11(1):102-7. PubMed ID: 26593062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
    Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
    Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
    Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
    Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
    Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
    J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting.
    Mascarin A; Valverde IE; Vomstein S; Mindt TL
    Bioconjug Chem; 2015 Oct; 26(10):2143-52. PubMed ID: 26347939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Neurotensin Receptor in Prostate Cancer With
    Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
    Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
    Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
    J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia.
    Poria RB; Norenberg JP; Anderson TL; Erion J; Wagner CR; Arterburn JB; Larson RS
    Cancer Biother Radiopharm; 2006 Oct; 21(5):418-26. PubMed ID: 17105416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.
    Sparr C; Purkayastha N; Yoshinari T; Seebach D; Maschauer S; Prante O; Hübner H; Gmeiner P; Kolesinska B; Cescato R; Waser B; Reubi JC
    Chem Biodivers; 2013 Dec; 10(12):2101-21. PubMed ID: 24327436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids.
    Magafa V; Matsoukas MT; Karageorgos V; Dermitzaki E; Exarchakou R; Stylos EΚ; Pardalos M; Margioris AN; Varvounis G; Tzakos AG; Spyroulias GA; Liapakis G
    Amino Acids; 2019 Jul; 51(7):1009-1022. PubMed ID: 31079216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, proteolytic stability, and
    Kaur J; Arroub K; Drzezga A; Schomäcker K; Mathur S
    Org Biomol Chem; 2021 Nov; 19(45):9849-9854. PubMed ID: 34755753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
    García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
    J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical PET Imaging of NTSR-1-Positive Tumors with
    Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE
    Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
    Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
    Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.
    Jamous M; Tamma ML; Gourni E; Waser B; Reubi JC; Maecke HR; Mansi R
    Nucl Med Biol; 2014 Jul; 41(6):464-70. PubMed ID: 24780298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric bioconjugates.
    Šimeček J; Hermann P; Havlíčková J; Herdtweck E; Kapp TG; Engelbogen N; Kessler H; Wester HJ; Notni J
    Chemistry; 2013 Jun; 19(24):7748-57. PubMed ID: 23613345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
    Lim JC; Hong YD; Kim JJ; Choi SM; Baek HS; Choi SJ
    Cancer Biother Radiopharm; 2012 Oct; 27(8):464-72. PubMed ID: 22831553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
    Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
    J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.